Xbiotech Priced, Nasdaq: XBIT
Developing antibodies for colorectal cancer and various other conditions.
Industry: Other
First Day Return: +22.4%
XBIT
Developing antibodies for colorectal cancer and various other conditions.
| IPO Data | |
|---|---|
| IPO Date | 04/14/2015 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $76 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Austin, TX, United States |
| Founded | 2005 |
| Employees at IPO | 56 |
| Website www.xbiotech.com | |
Xbiotech (XBIT) Performance
